(CercleFinance.com) – Biocorp announces, following obtaining the usual regulatory authorizations, the completion of the off-market acquisition by Novo Nordisk of a total of 2,838,669 shares, i.e. 64.3% of the capital and 64, 09% of the voting rights of the company, for a price of 35 euros per share.
The outstanding convertible bonds issued by Biocorp were fully redeemed in cash on this occasion and the composition of Biocorp’s board of directors was modified to take into account the new configuration of its shareholding.
Novo Nordisk will file with the AMF in the coming days a draft mandatory simplified tender offer (OPAS) with a view to acquiring the balance of the shares, then will proceed with the squeeze-out in the event that the required conditions are met. reached.